Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of EB8018 in Healthy Volunteers
NCT02998190Phase 1Completed
- Sponsor
- Enterome
- Start
- Nov 2016
- Primary completion
- Apr 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of sibofimloc in Crohn's disease (4 arms), sponsored by Enterome. Primary endpoint: Treatment Related Adverse Events. Started Nov 2016; status: completed.
02
Drugs
sibofimloc
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT02998190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02998190.